Fair Lawn, NJ (July 27, 2004) - Lonza has signed an exclusive agreement with Innovite, an Oregon-based company specializing in the manufacture of sustained-release Niacin tablets, to manufacture Niamax™.
Under this agreement Lonza will offer Niamax™ in bulk, in form of a unique 500 mg sustained-release tablet to the U.S. Nutrition Industry. The Niamax™ formulation uses Lonza’s Niacin USP Granular material.
Niamax™ a trademark of Lonza Ltd., has been proven in several human clinical trials to work on the entire cholesterol profile, supporting healthier total cholesterol, LDL-cholesterol and triglyceride levels, as well as raising HDL-cholesterol. Nia-max™ has also been shown to reduce flushing, a common side-effect and complaint associated with standard Niacin tablets. In fact, the Niamax™ formulation was very well-tolerated by patients in numerous studies.
The National Institute of Health (NIH) recommends Niacin as a “first-line” therapy for people with abnormal or unhealthy cholesterol levels.
Niamax™ offers an affordable solution as a dietary supplement backed by sound scientific studies to benefit the entire cholesterol profile.
Lonza is a life sciences driven company, headquartered in Switzerland, which generated sales of CHF 2.24 billion in 2003. It operates 18 production and R&D facili-ties in eight countries and employs 5660 people worldwide. Lonza is one of the leading custom manufacturers of chemical intermediates and active ingredients as well as biopharmaceuticals for the pharmaceutical and agrochemical industries. In addition, Lonza also offers organic intermediates for a wide range of applications and provides antimicrobial and associated products as well as polymer intermediates and compounds. For more information please visit the company’s website at www.lonza.com.
Tel +1 201 794 2448
Fax +1 201 794 2695